Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 5/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30265414 | 0.88 | HTT (0.58) | HTTL3MBTL1HDAC6POLBTDP1 | |
| SCHEMBL30265100 | 0.87 | HTT (0.65) | HTTL3MBTL1HDAC6POLBTDP1 | |
| SCHEMBL30265434 | 0.84 | HTT (0.72) | HTTL3MBTL1HDAC6POLBTDP1 | |
| SCHEMBL23979000 | 0.83 | HTT (0.74) | HTTL3MBTL1HDAC6POLBTDP1 | |
| SCHEMBL30265356 | 0.83 | HTT (0.70) | HTTL3MBTL1HDAC6POLBTDP1 | |
| SCHEMBL30265129 | 0.82 | HTT (0.69) | HTTL3MBTL1HDAC6POLBTDP1 | |
| Hydrochloric Acid SCHEMBL30265086 | 0.82 | HTT (0.69) | HTTL3MBTL1HDAC6POLBTDP1 | |
| SCHEMBL30265304 | 0.82 | HTT (0.73) | HTTL3MBTL1HDAC6POLBTDP1 | |
| SCHEMBL30265274 | 0.82 | HTT (0.73) | HTTL3MBTL1HDAC6POLBTDP1 | |
| SCHEMBL30265199 | 0.81 | HTT (0.71) | HTTL3MBTL1HDAC6POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | VTV THERAPEUTICS LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | VTV THERAPEUTICS LLC | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | ALDH1A2, UACA, PDE6D | HTT 4721/4885L3MBTL1 4608/4885HDAC6 154/4885 |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | HBB, HBZ, HBG1 | HTT 311/4885L3MBTL1 824/4885HDAC6 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.